多发伤患者血清高迁移率族蛋白B1及可溶性髓样细胞触发受体-1水平变化及预后意义

doi:10.3969/j.issn.1674-8115.2024.03.007

上海交通大学学报（医学版） ›› 2024, Vol. 44 ›› Issue (3): 350-357.doi: 10.3969/j.issn.1674-8115.2024.03.007

• 论著 · 临床研究 • 上一篇

多发伤患者血清高迁移率族蛋白B1及可溶性髓样细胞触发受体-1水平变化及预后意义

王桂杰(), 杜传冲, 陆叶, 赵健, 沈勰, 金冬林, 耿佳财()

江苏省苏州市第九人民医院急诊医学科，苏州 215000

收稿日期:2023-07-14 接受日期:2024-01-02 出版日期:2024-03-28 发布日期:2024-04-29
通讯作者: 耿佳财 E-mail:15370041964@163.com;chpany@126.com
作者简介:王桂杰（1986—），男，主治医师，硕士；电子信箱：15370041964@163.com。
基金资助:
2022年苏州市第九人民医院院级科研基金(YK202216)

Changes of serum high mobility group box 1 and soluble triggering receptor expressed on myeloid cells-1 in patients with multiple injuries and their prognostic significance

WANG Guijie(), DU Chuanchong, LU Ye, ZHAO Jian, SHEN Xie, JIN Donglin, GENG Jiacai()

Department of Emergency Medicine, Suzhou Ninth People′s Hospital, Jiangsu Province, Suzhou 215000, China

Received:2023-07-14 Accepted:2024-01-02 Online:2024-03-28 Published:2024-04-29
Contact: GENG Jiacai E-mail:15370041964@163.com;chpany@126.com
Supported by:
2022 Hospital-level Scientific Research Fund of Suzhou Ninth People′s Hospital(YK202216)

摘要/Abstract

摘要：

目的·检测多发伤患者不同时间点的血清高迁移率族蛋白B1（high mobility group box 1，HMGB1）及可溶性髓样细胞触发受体-1（soluble triggering receptor expressed on myeloid cell-1，sTREM-1）水平，并分析其与病情严重程度、并发症及预后的相关性。方法·选取2020年12月至2022年12月在苏州市第九人民医院急诊科收治的多发伤患者92例，根据患者入院时的损伤严重程度评分将患者分为轻伤组（n=24）、重伤组（n=58）、严重伤组（n=10）；依据入院后是否合并多器官功能障碍综合征（multiple organ dysfunction syndrome，MODS）将患者分为MODS组（n=20）和非MODS组（n=72）；根据创伤发生后28 d内结局将患者分为死亡组（n=13）和存活组（n=79）。检测患者入院后静脉血炎症因子指标。采用酶联免疫吸附试验（enzyme linked immunosorbent assay，ELISA）检测创伤发生后24 h、72 h及7 d的血清HMGB1、sTREM-1水平。分析不同分组间血清HMGB1、sTREM-1水平的差异，并采用多因素Logistic回归分析多发伤患者不良结局的影响因素。运用受试者工作特征（receiver operating characteristics，ROC）曲线评估HMGB1、sTREM-1对不良结局的预测价值。结果·重伤和严重伤组各时间点HMGB1、sTREM-1水平明显高于轻伤组（均P<0.05），严重伤组创伤发生后72 h和7 d的HMGB1水平及24 h和72 h的sTREM-1水平明显高于重伤组（均P<0.05）。各时间点HMGB1与sTREM-1水平呈正相关性（r=0.645，r=0.942，r=0.722；均P<0.05）。MODS组创伤发生后72 h和7 d的HMGB1水平及24 h和72 h的sTREM-1水平明显高于非MODS组（均P<0.05）；死亡组创伤发生后72 h和7 d的HMGB1水平及24 h、72 h的sTREM-1水平明显高于存活组（均P<0.05）。Logistic回归分析显示，创伤发生后7 d的HMGB1水平及入院时间、超敏C反应蛋白（hypersensitive C-reactive protein，hs-CRP）水平是多发伤患者不良结局的独立影响因素（均P<0.05）。ROC曲线显示，创伤发生后7 d的HMGB1水平预测不良预后的曲线下面积为0.890，敏感度为83.5%，特异度为92.3%。结论·多发伤患者创伤发生后不同时间点HMGB1及sTREM-1水平与MODS及生存结局相关，且创伤发生后7 d的HMGB1水平是多发伤患者不良结局的独立影响因素。

关键词: 多发伤, 高迁移率族蛋白B1, 可溶性髓样细胞触发受体-1, 预后

Abstract:

Objective ·To detect the serum levels of high mobility group box 1 (HMGB1) and soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) in patients with multiple injuries at different time points, and to analyze their correlation with disease severity, complications and prognosis. Methods ·Ninety-two patients with multiple injuries admitted to the Department of Emergency Medicine of the Suzhou Ninth People′s Hospital from December 2020 to December 2022 were selected. According to the injury severity scores of the patients at admission, the patients were divided into light injury group (n=24), grave injury group (n=58) and severe injury group (n=10). According to whether there was multiple organ dysfunction syndrome (MODS) after admission, the patients were divided into MODS group (n=20) and non-MODS group (n=72). According to the outcome within 28 d after trauma, the patients were divided into death group (n=13) and survival group (n=79). Inflammatory factor indicators in venous blood of patients after admission were detected. Enzyme linked immunosorbent assay (ELISA) was used to detect the serum HMGB1 and sTREM-1 levels at 24 h, 72 h and 7 d after trauma, and the differences of serum HMGB1 and sTREM-1 levels among different groups were analyzed. Multiple Logistic regression was used to analyze the influencing factors of adverse outcomes in patients with multiple injuries. The receiver operating characteristic (ROC) curve was used to evaluate the predictive value of HMGB1 and sTREM-1 for adverse outcomes. Results ·The levels of HMGB1 and sTREM-1 in the grave injury and severe injury groups were significantly higher than those in the light injury group (P<0.05). The levels of HMGB1 at 72 h and 7 d, and sTREM-1 at 24 h and 72 h in the severe injury group were significantly higher than those in the grave injury group (P<0.05). There was a positive correlation between HMGB1 and sTREM-1 levels at various time points (r=0.645, r=0.942, r=0.722; all P<0.05). The levels of HMGB1 at 72 h and 7 d, and sTREM-1 at 24 h and 72 h in the MODS group were significantly higher than those in the non-MODS group (all P<0.05). The levels of HMGB1 at 72 h and 7 d, and sTREM-1 at 24 h and 72 h in the death group were significantly higher than those in the survival group (all P<0.05). Logistic regression analysis showed that HMGB1 at 7 d, admission time and hypersensitive C-reactive protein (hs-CRP) were independent factors of adverse outcomes in patients with multiple injuries (all P<0.05). The ROC curve showed that the area under the curve of HMGB1 for predicting poor prognosis at 7 days after trauma was 0.890, the sensitivity was 83.5%, and the specificity was 92.3%. Conclusion ·The levels of HMGB1 and sTREM-1 are correlated with MODS and survival outcomes in patients with multiple injuries at different time points after trauma, and HMGB1 at 7 d after trauma is an independent factor affecting adverse outcomes in patients with multiple injuries.

Key words: multiple injury, high mobility group box 1 (HMGB1), soluble triggering receptor expressed on myeloid cell-1 (sTREM-1), prognosis

中图分类号:

R459.7

王桂杰, 杜传冲, 陆叶, 赵健, 沈勰, 金冬林, 耿佳财. 多发伤患者血清高迁移率族蛋白B1及可溶性髓样细胞触发受体-1水平变化及预后意义[J]. 上海交通大学学报（医学版）, 2024, 44(3): 350-357.

WANG Guijie, DU Chuanchong, LU Ye, ZHAO Jian, SHEN Xie, JIN Donglin, GENG Jiacai. Changes of serum high mobility group box 1 and soluble triggering receptor expressed on myeloid cells-1 in patients with multiple injuries and their prognostic significance[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(3): 350-357.

图/表 7

参考文献 28

1	TACHINO J, KATAYAMA Y, KITAMURA T, et al. Assessment of the interaction effect between injury regions in multiple injuries: a nationwide cohort study in Japan[J]. J Trauma Acute Care Surg, 2021, 90(1): 185-190.
2	SANDSTRÖM L, ENGSTRÖM Å, NILSSON C, et al. Experiences of suffering multiple trauma: a qualitative study[J]. Intensive Crit Care Nurs, 2019, 54: 1-6.
3	LINGITZ M T, WOLLNER G, BAUER J, et al. Elevation of neutrophil-derived factors in patients after multiple trauma[J]. J Cell Mol Med, 2023, 27(13): 1859-1866.
4	RELJA B, YANG B, BUNDKIRCHEN K, et al. Different experimental multiple trauma models induce comparable inflammation and organ injury[J]. Sci Rep, 2020, 10(1): 20185.
5	XUE J M, SUAREZ J S, MINAAI M, et al. HMGB1 as a therapeutic target in disease[J]. J Cell Physiol, 2021, 236(5): 3406-3419.
6	PATOULIAS D, KALOGIROU M S, PATOULIAS I. Triggering receptor expressed on myeloid cells-1 (TREM-1) and its soluble in the plasma form (sTREM-1) as a diagnostic biomarker in neonatal sepsis[J]. Folia Med Cracov, 2018, 58(2): 15-19.
7	PAKNEJAD M, SATTARI M, ROOZBAHANI Z, et al. Relationships between high-mobility group protein B1 and triggering receptor expressed on myeloid cells concentrations in gingival crevicular fluid and chronic periodontitis[J]. Iran J Allergy Asthma Immunol, 2016, 15(5): 381-385.
8	POLITO F, CICCIU′ M, AGUENNOUZ M, et al. Prognostic value of HMGB1 and oxidative stress markers in multiple trauma patients: a single-centre prospective study[J]. Int J Immunopathol Pharmacol, 2016, 29(3): 504-509.
9	ZHENG S Q, ZHANG W. Predictive values of sTREM-1, PCT and CRP for multiple trauma-induced acute respiratory distress syndrome complicated with pulmonary infection[J]. Clin Lab, 2022, 68(12). DOI: 10.7754/Clin.Lab.2022.211258.
10	中华医学会创伤学分会创伤急救与多发伤学组. 多发伤病历与诊断: 专家共识意见(2013版)[J]. 创伤外科杂志, 2014, 16(2): 192.
	Trauma Care and Multiple Injury Group of Traumatology Society of Chinese Medical Association. Consensus on medical documentation and diagnosis of multiple injury[J]. Journal of Traumatic Surgery, 2014, 16(2): 192.
11	李阳, 张连阳. 简明损伤定级/损伤严重度评分的研究进展与误用解析[J]. 中华创伤杂志, 2021, 37(1): 11-14.
	LI Y, ZHANG L Y. Research progress and error analysis of abbreviated injury scale/injury severity score[J]. Chinese Journal of Trauma, 2021, 37(1): 11-14.
12	中华医学会创伤学分会创伤感染学组, 中华医学会创伤学分会创伤急救与多发伤学组. 创伤后并发症的定义与诊断专家共识[J]. 中华创伤杂志, 2013, 29(6): 481-484.
	Trauma Infection Group, Trauma First Aid and Multiple Injury Group, Chinese Society of Trauma, Chinese Society of Trauma. Expert consensus on the definition and diagnosis of post-traumatic complications[J]. Chinese Journal of Trauma, 2013, 29(6): 481-484.
13	BERWIN J T, PEARCE O, HARRIES L, et al. Managing polytrauma patients[J]. Injury, 2020, 51(10): 2091-2096.
14	舒小燚, 范绍辉, 徐宇, 等. 高迁移率族蛋白B1在ARDS中的释放机制研究进展[J]. 中华危重病急救医学, 2021, 33(7): 889-893.
	SHU X Y, FAN S H, XU Y, et al. Research progress on release mechanism of high mobility group protein B1 in acute respiratory distress syndrome[J]. Chinese Critical Care Medicine, 2021, 33(7): 889-893.
15	WANG S M, ZHANG Y. HMGB1 in inflammation and cancer[J]. J Hematol Oncol, 2020, 13(1): 116.
16	VIJAYAKUMAR E C, BHATT L K, PRABHAVALKAR K S. High mobility group box-1 (HMGB1): a potential target in therapeutics[J]. Curr Drug Targets, 2019, 20(14): 1474-1485.
17	OTTESTAD W, ROGNES I N, PISCHKE S E, et al. Biphasic release of the alarmin high mobility group box 1 protein early after trauma predicts poor clinical outcome[J]. Crit Care Med, 2019, 47(8): e614-e622.
18	王海, 黎世贵. 血清高迁移率族蛋白B1及降钙素原对创伤性脑损伤患者预后评估的价值[J]. 中国急救医学, 2020, 40(5): 417-421.
	WANG H, LI S G. Prognostic value of serum high mobility group protein B1 and procalcitonin in the patients with traumatic brain injury[J]. Chinese Journal of Critical Care Medicine, 2020, 40(5): 417-421.
19	YANG Z S, SIMOVIC M O, EDSALL P R, et al. HMGB1 inhibition to ameliorate organ failure and increase survival in trauma[J]. Biomolecules, 2022, 12(1): 101.
20	刘发生, 李帅, 郭立峰, 等. HMGB-1、cTnI及Ang2与急诊多发伤血管损伤、院内死亡风险的关系[J]. 分子诊断与治疗杂志, 2021, 13(8): 1349-1352.
	LIU F S, LI S, GUO L F, et al. The relationship between the levels of HMGB-1, cTnI and Ang2 and vascular endothelial injury and the risk of hospital death in patients with multiple injuries in the emergency department[J]. Journal of Molecular Diagnosis and Therapy, 2021, 13(8): 1349-1352.
21	宋超, 蔡华忠, 周峰, 等. 血清HMGB-1、Mb、CK、IL-6水平预测急性腹部多发伤病情严重程度的意义[J]. 中国现代普通外科进展, 2020, 23(1): 27-30.
	SONG C, CAI H Z, ZHOU F, et al. Predictive value of serum HMGB-1,Mb,CK,IL-6 indicators in patients with acute abdominal multiple trauma on severity and prognosis[J]. Chinese Journal of Current Advances in General Surgery, 2020, 23(1): 27-30.
22	PIVA S, ALBANI F, FAGONI N, et al. High-mobility group box-1 protein as a novel biomarker to diagnose healthcare-associated ventriculitis and meningitis: a pilot study[J]. Minerva Anestesiol, 2021, 87(1): 43-51.
23	杜奇容, 潘曙明, 李明, 等. 血清标志物联合急性生理与慢性健康评分在多发伤并多器官功能障碍综合征诊断及预后中的价值[J]. 中国临床医生杂志, 2022, 50(2): 181-184.
	DU Q R, PAN S M, LI M, et al. The value of serum markers combined with acute physiology and chronic health evaluation score in the diagnosis and prognosis of multiple trauma with multiple organ dysfunction syndrome[J]. Chinese Journal for Clinicians, 2022, 50(2): 181-184.
24	FENG J Y, SU W J, PAN S W, et al. Role of TREM-1 in pulmonary tuberculosis patients: analysis of serum soluble TREM-1 levels[J]. Sci Rep, 2018, 8(1): 8223.
25	CHEN M K, ZHU Y. Utility of sTREM-1 and presepsin (sCD14-ST) as diagnostic and prognostic markers of sepsis[J]. Clin Lab, 2020, 66(4). DOI: 10.7754/Clin.Lab.2019.190508.
26	TRANCĂ S, OEVER J T, CIUCE C, et al. sTREM-1, sIL-2Rα, and IL-6, but not sCD163, might predict sepsis in polytrauma patients: a prospective cohort study[J]. Eur J Trauma Emerg Surg, 2017, 43(3): 363-370.
27	茅尧生, 李智鑫, 吕铁, 等. 可溶性髓样细胞表达触发受体-1对多发伤患者并发脓毒症的早期诊断和预后判断的意义[J]. 中华创伤杂志, 2015, 31(12): 1102-1105.
	MAO Y S, LI Z X, LV T, et al. The significance of soluble triggering receptor expressed on myeloid cells-1 in the early diagnosis and prognosis of sepsis in patients with multiple trauma[J]. Chinese Journal of Trauma, 2015, 31(12): 1102-1105.
28	马玉东, 孟凡鑫, 宋岩. 可溶性髓样细胞触发受体-1与严重多发伤后MODS的相关性[J]. 山东医药, 2013, 53(4): 11-13.
	MA Y D, MENG F X, SONG Y. Relevance of the soluble triggering receptors expressed on myeloid cells-1 with multiple organ dysfunction syndrome after severe multiple trauma[J]. Shandong Medicine, 2013, 53(4): 11-13.

Variable	Light injury group (n=24)	Grave injury group (n=58)	Severe injury group (n=10)	P value^③	P value^④	P value^⑤
HMGB1/(ng·mL^-1)^①
24 h	2.47±0.61	2.86±0.65	2.99±0.52	0.013	0.030	0.531
72 h	3.12±0.73	3.57±0.66	4.22±0.31	0.006	0.000	0.005
7 d	3.63±0.83	4.19±0.77	4.96±0.35	0.003	0.000	0.004
sTREM-1/(ng·mL^-1)^②
24 h	11.71±3.00	13.43±2.65	15.38±1.95	0.010	0.000	0.037
72 h	12.77±3.47	14.46±2.74	16.51±1.99	0.017	0.001	0.041
7 d	5.52±1.24	6.47±1.25	6.72±1.20	0.006	0.015	0.463

Variable	Light injury group (n=24)	Grave injury group (n=58)	Severe injury group (n=10)	P value^③	P value^④	P value^⑤
HMGB1/(ng·mL^-1)^①
24 h	2.47±0.61	2.86±0.65	2.99±0.52	0.013	0.030	0.531
72 h	3.12±0.73	3.57±0.66	4.22±0.31	0.006	0.000	0.005
7 d	3.63±0.83	4.19±0.77	4.96±0.35	0.003	0.000	0.004
sTREM-1/(ng·mL^-1)^②
24 h	11.71±3.00	13.43±2.65	15.38±1.95	0.010	0.000	0.037
72 h	12.77±3.47	14.46±2.74	16.51±1.99	0.017	0.001	0.041
7 d	5.52±1.24	6.47±1.25	6.72±1.20	0.006	0.015	0.463

Variable	Non-MODS group (n=72)	MODS group (n=20)	P value
HMGB1/(ng·mL^-1)^①
24 h	2.71±0.65	2.99±0.60	0.086
72 h	3.42±0.70	3.88±0.66	0.011
7 d	4.01±0.82	4.57±0.76	0.008
sTREM-1/(ng·mL^-1)^②
24 h	12.83±2.77	14.50±2.87	0.020
72 h	13.84±2.96	15.71±2.97	0.014
7 d	6.07±1.20	6.69±1.71	0.069

Variable	Non-MODS group (n=72)	MODS group (n=20)	P value
HMGB1/(ng·mL^-1)^①
24 h	2.71±0.65	2.99±0.60	0.086
72 h	3.42±0.70	3.88±0.66	0.011
7 d	4.01±0.82	4.57±0.76	0.008
sTREM-1/(ng·mL^-1)^②
24 h	12.83±2.77	14.50±2.87	0.020
72 h	13.84±2.96	15.71±2.97	0.014
7 d	6.07±1.20	6.69±1.71	0.069

Variable	Survival group (n=79)	Death group (n=13)	t/χ² value	P value
Age/year	42.53±11.64	47.31±11.71	1.369	0.174
Gender/n(%)			0.837	0.546
Male	44 (55.70)	9 (69.23)
Female	35 (40.30)	4 (30.77)
Background disease/n(%)			0.387	0.747
Yes	25 (31.65)	3 (23.08)
No	54 (68.35)	10 (76.92)
Admission time/h	4.43±0.92	5.00±0.51	3.259	0.003
Injury factor/n(%)			1.224	0.570
Transportation	54 (68.35)	8 (61.54)
Fall accident from high place	19 (24.05)	3 (23.08)
Other	6 (7.59)	2 (15.38)
Number of wound sites/n	2.66±0.64	2.92±0.49	1.425	0.158
Primary trauma site/n(%)			7.400	0.042
Head	32 (40.51)	11 (84.62)
Chest	27 (34.18)	1 (7.69)
Abdomen	14 (17.72)	1 (7.69)
Limbs and pelvis	6 (7.59)	0 (0)
Emergency operation/n(%)			2.391	0.181
Yes	20 (25.32)	6 (46.15)
No	59 (74.68)	7 (53.85)
Massive transfusion/n(%)			4.778	0.055
Yes	24 (34.18)	8 (61.54)
No	55 (65.82)	5 (38.46)
Severity/n(%)			19.475	0.000
Lightly injury	22 (27.85)	2 (15.38)
Gravely injury	54 (68.35)	4 (30.77)
Severe injury	3 (3.80)	7 (53.85)
GCS score/score	10.31±2.04	9.51±2.27	1.286	0.202
APTT/s	30.31±5.02	32.97±5.91	1.727	0.088
DD/(mg·L^-1)	0.81±0.37	0.89±0.29	0.770	0.443
MODS/n(%)			5.304	0.032
Yes	14 (17.72)	6 (46.15)
No	65 (82.28)	7 (53.85)
hs-CRP/(mg·L^-1)	18.74±3.98	21.79±3.28	2.612	0.011
IL-6/(pg·mL^-1)	65.16±14.11	78.33±10.46	3.215	0.002
PCT/(ng·mL^-1)	4.06±0.90	5.02±0.91	3.560	0.001

多发伤患者血清高迁移率族蛋白B1及可溶性髓样细胞触发受体-1水平变化及预后意义

Changes of serum high mobility group box 1 and soluble triggering receptor expressed on myeloid cells-1 in patients with multiple injuries and their prognostic significance

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 7

参考文献 28

相关文章 15

编辑推荐

Metrics

Variable	Survival group (n=79)	Death group (n=13)	P value
HMGB1/(ng·mL^-1)^①
24 h	2.73±0.65	3.05±0.57	0.096
72 h	3.40±0.69	4.23±0.43	0.000
7d	3.97±0.79	5.07±0.44	0.000
sTREM-1/(ng·mL^-1)^②
24 h	12.78±2.75	15.70±2.21	0.000
72 h	13.68±2.79	17.66±2.23	0.000
7 d	6.16±1.30	6.92±1.20	0.106

Variable	B	Wals	Sig	OR	95% CI
Admission time	1.320	4.136	0.042	3.743	1.049‒13.358
hs-CRP	0.416	8.247	0.004	1.516	1.141‒2.014
HMGB1_{7 d}	3.572	12.131	0.011	35.600	4.769‒265.752

[1]	杜沚珊, 王玥, 石子旸, 施晴, 易红梅, 董磊, 王黎, 程澍, 许彭鹏, 赵维莅. 甲状腺弥漫性大B细胞淋巴瘤临床病理特征、基因突变谱及预后分析[J]. 上海交通大学学报（医学版）, 2024, 44(1): 64-71.
[2]	骆梦醒, 邹欣, 高雅娴, 吴小翠, 余方友, 胡洋, 曾奇兵, 刘忠华. 结核病合并基础疾病患者的抗结核治疗效果及肺部损伤分析[J]. 上海交通大学学报（医学版）, 2023, 43(8): 1017-1023.
[3]	李瑛, 谭阳霞, 尹虹心, 蒋雁翎, 陈立, 蒙国宇. ZNF384融合亚型急性白血病的发病机制及预后研究进展[J]. 上海交通大学学报（医学版）, 2023, 43(5): 631-640.
[4]	门如, 朱旻霞, 张伟明. 维持性血液透析患者血钾水平及其对预后影响[J]. 上海交通大学学报（医学版）, 2023, 43(4): 507-513.
[5]	王安君, 刘宁宁. 放疗对行化疗和手术的直肠癌患者的效果分析：一项基于SEER数据库的回顾性研究[J]. 上海交通大学学报（医学版）, 2023, 43(3): 320-332.
[6]	李芳, 李凯杨, 王珏, 晏睿阳, 沈慧, 刘敏. PLA2G2A在肾乳头状细胞癌中的表达及临床意义[J]. 上海交通大学学报（医学版）, 2023, 43(2): 152-161.
[7]	赵洁, 姜言, 郝思国. 弥漫大B细胞淋巴瘤患者临床特征及预后分析[J]. 上海交通大学学报（医学版）, 2023, 43(10): 1282-1288.
[8]	后书敏, 邵静波. TdT阴性的淋巴母细胞淋巴瘤/急性淋巴细胞白血病临床特点、诊断及预后研究进展[J]. 上海交通大学学报（医学版）, 2023, 43(1): 120-124.
[9]	邱佳辉, 蔡谦谦, 杨彦, 程非池, 裘正军, 黄陈. 神经脉管浸润联合肿瘤间质比对结直肠癌预后的预测价值[J]. 上海交通大学学报（医学版）, 2022, 42(8): 1070-1080.
[10]	卫雪敏, 高成金. ASPECT评分在急性缺血性脑卒中临床应用中的研究进展[J]. 上海交通大学学报（医学版）, 2022, 42(7): 919-924.
[11]	董亚兵, 郝昀博, 张文豪, 王轶雯, 陈敏洁. 下颌第三磨牙拔除术后下牙槽神经损伤的功能检测及预后分析[J]. 上海交通大学学报（医学版）, 2022, 42(6): 717-722.
[12]	朱田雨, 宗春燕, 许诗琼, 葛盛芳, 范先群, 贾仁兵. 结膜黑色素瘤组织病理学特征、Ki-67表达和预后的关系[J]. 上海交通大学学报（医学版）, 2022, 42(5): 617-623.
[13]	向晗, 向武, 张伟国. 获得性囊性肾病相关肾细胞癌的研究进展[J]. 上海交通大学学报（医学版）, 2022, 42(5): 680-684.
[14]	邢正文, 吴滢, 王雪莉, 王庆煜, 王文婷, 李治, 张彬, 金晶. 8例儿童卵巢颗粒细胞瘤临床病理特征及预后分析[J]. 上海交通大学学报(医学版), 2022, 42(2): 192-196.
[15]	赵雪, 董春燕. WD40重复蛋白43在肺腺癌中的表达及其对细胞紫杉醇耐药的影响[J]. 上海交通大学学报（医学版）, 2022, 42(12): 1656-1665.